Scholarlink

Background <p>This study aimed to compare the utility of 3’-deoxy-3’-¹⁸F-fluorothymidine (FLT) positron emission tomography (PET) and 2-deoxy-2-¹⁸F-fluoro-D-glucose (FDG) PET in predicting pathological response to neoadjuvant chemoradiotherapy (nCRT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC), and retrospectively evaluated 21 patients who underwent FLT and FDG PET before and after nCRT. The maximum standardised uptake value (SUVmax) of the primary tumour was measured pre- and post-nCRT, and the percentage reduction in SUVmax (%ΔSUVmax) was calculated. Pathological response was assessed using the Evans grading system, with Grades I–IIa defined as non-responders and Grades IIb–IV as responders. Mann-Whitney U tests and receiver operating characteristic (ROC) analyses were performed.</p> Results <p>Three patients with blood glucose levels ≥ 200&#xa0;mg/dL at pre-nCRT FDG PET were excluded from FDG PET analysis. Surgical specimens classified nine patients as responders and 12 as non-responders. SUVmax_pre-nCRT did not differ significantly between groups for either modality. SUVmax_post-nCRT was significantly lower in responders for both FLT (<i>P</i> = 0.001) and FDG (<i>P</i> = 0.009) PET. A significant %ΔSUVmax difference was observed only with FLT PET (<i>P</i> = 0.002). Areas under the curve for predicting response to nCRT were: FLT SUVmax_post-nCRT (0.90), FLT %ΔSUVmax (0.89), and FDG SUVmax_post-nCRT (0.86).</p> Conclusion <p>FLT PET demonstrated comparable performance to FDG PET in assessing response to nCRT in resectable and borderline resectable PDAC, with potential as a complementary or alternative imaging modality in neoadjuvant settings given its independence from glycaemic status and biological proliferation specificity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predicting pathological response to neoadjuvant chemoradiotherapy in resectable and borderline resectable pancreatic ductal adenocarcinoma: a comparative study of 18F-FLT and 18F-FDG PET

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月1日

查看全文
  • Takashi Norikane,
  • Kengo Fujimoto,
  • Hiroyuki Matsukawa,
  • Yuri Manabe,
  • Mitsumasa Murao,
  • Riku Morita,
  • Katsuya Mitamura,
  • Yuka Yamamoto,
  • Naruhide Kimura,
  • Keiichi Okano,
  • Yoshihiro Nishiyama

摘要

Background

This study aimed to compare the utility of 3’-deoxy-3’-¹⁸F-fluorothymidine (FLT) positron emission tomography (PET) and 2-deoxy-2-¹⁸F-fluoro-D-glucose (FDG) PET in predicting pathological response to neoadjuvant chemoradiotherapy (nCRT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC), and retrospectively evaluated 21 patients who underwent FLT and FDG PET before and after nCRT. The maximum standardised uptake value (SUVmax) of the primary tumour was measured pre- and post-nCRT, and the percentage reduction in SUVmax (%ΔSUVmax) was calculated. Pathological response was assessed using the Evans grading system, with Grades I–IIa defined as non-responders and Grades IIb–IV as responders. Mann-Whitney U tests and receiver operating characteristic (ROC) analyses were performed.

Results

Three patients with blood glucose levels ≥ 200 mg/dL at pre-nCRT FDG PET were excluded from FDG PET analysis. Surgical specimens classified nine patients as responders and 12 as non-responders. SUVmax_pre-nCRT did not differ significantly between groups for either modality. SUVmax_post-nCRT was significantly lower in responders for both FLT (P = 0.001) and FDG (P = 0.009) PET. A significant %ΔSUVmax difference was observed only with FLT PET (P = 0.002). Areas under the curve for predicting response to nCRT were: FLT SUVmax_post-nCRT (0.90), FLT %ΔSUVmax (0.89), and FDG SUVmax_post-nCRT (0.86).

Conclusion

FLT PET demonstrated comparable performance to FDG PET in assessing response to nCRT in resectable and borderline resectable PDAC, with potential as a complementary or alternative imaging modality in neoadjuvant settings given its independence from glycaemic status and biological proliferation specificity.